Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Florence Wong, Thomas D Boyer, Arun J Sanyal, Stephen C Pappas, Shannon Escalante, Khurram Jamil
BACKGROUND: Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated. The impact of reduction in AKI stage on overall survival in cirrhosis, independent of HRS reversal, is unclear. METHODS: The Randomized, placEbo-controlled, double-blind study to confirm the reVERSal of HRS-1 with terlipressin study assessed terlipressin versus placebo, both with albumin, as treatment for HRS-1 for ≤14 days...
March 18, 2019: Nephrology, Dialysis, Transplantation
#2
Alexandru Burlacu, Simonetta Genovesi, Alberto Ortiz, Christian Combe, Carlo Basile, Daniel Schneditz, Frank van der Sande, Grigore T Popa, Cornel Morosanu, Adrian Covic
Dialysis patients manifest both an increased thrombotic risk and a haemorrhagic tendency. A great number of patients with chronic kidney disease requiring dialysis have cardiovascular comorbidities (coronary artery disease, atrial fibrillation or venous thromboembolism) and different indications for treatment with antithrombotics (primary or secondary prevention). Unfortunately, few randomized controlled trials deal with antiplatelet and/or anticoagulant therapy in dialysis. Therefore cardiology and nephrology guidelines offer ambiguous recommendations and often exclude or ignore these patients...
March 16, 2019: Nephrology, Dialysis, Transplantation
#3
Shubha S Bellur, Ian S D Roberts, Stéphan Troyanov, Virginie Royal, Rosanna Coppo, H Terence Cook, Daniel Cattran, Yolanda Arce Terroba, Anna Maria Asunis, Ingeborg Bajema, Elisabetta Bertoni, Jan A Bruijn, Pablo Cannata-Ortiz, Donatella Casartelli, Anna Maria Di Palma, Franco Ferrario, Mirella Fortunato, Luciana Furci, Hariklia Gakiopoulou, Danica Galesic Ljubanovic, Konstantinos Giannakakis, Montserrat Gomà, Hermann-Josef Gröne, Eduardo Gutiérrez, S Asma Haider, Eva Honsova, Elli Ioachim, Henryk Karkoszka, David Kipgen, Jagoda Maldyk, Gianna Mazzucco, Diclehan Orhan, Yasemin Ozluk, Afroditi Pantzaki, Agnieszka Perkowska-Ptasinska, Zivili Riispere, Magnus P Soderberg, Eric Steenbergen, Antonella Stoppacciaro, Birgitta Sundelin Von Feilitzen, Regina Tardanico
No abstract text is available yet for this article.
March 16, 2019: Nephrology, Dialysis, Transplantation
#4
Anqun Chen, Kyung Lee, Tianjun Guan, John Cijiang He, Detlef Schlondorff
Crescentic glomerulonephritis (cGN) comprises three main types according to the pathogenesis and immunofluorescence patterns: anti-glomerular basement membrane antibody cGN, vasculitis-associated cGN and post-infectious immune complex cGN. In this brief review of the immune-pathogenesis of cGN, the focus is mainly on the role of CD8+ T cells in the progression of cGN. Under control conditions, Bowman's capsule (BC) provides a protected immunological niche by preventing access of cytotoxic CD8+ T cells to Bowman's space and thereby podocytes...
March 16, 2019: Nephrology, Dialysis, Transplantation
#5
Stephanie M Toth-Manikowski, Tammy L Sirich, Timothy W Meyer, Thomas H Hostetter, Seungyoung Hwang, Natalie S Plummer, Xin Hai, Josef Coresh, Neil R Powe, Tariq Shafi
BACKGROUND: Residual kidney function (RKF) is thought to exert beneficial effects through clearance of uremic toxins. However, the level of native kidney function where clearance becomes negligible is not known. METHODS: We aimed to assess whether levels of nonurea solutes differed among patients with 'clinically negligible' RKF compared with those with no RKF. The hemodialysis study excluded patients with urinary urea clearance >1.5 mL/min, below which RKF was considered to be 'clinically negligible'...
March 15, 2019: Nephrology, Dialysis, Transplantation
#6
David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt, Kevin J Martin, Anjay Rastogi, Pablo Ureña-Torres, Marc Vervloet, Geoffrey A Block
BACKGROUND: Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. This open-label extension (OLE) trial evaluated the long-term effects of etelcalcetide for sHPT treatment in patients receiving hemodialysis. METHODS: This 52-week, multicenter, single-arm OLE enrolled patients from three parent trials: two randomized, double-blind, placebo-controlled trials and one open-label, single-arm, 'switch' study from cinacalcet to etelcalcetide...
March 11, 2019: Nephrology, Dialysis, Transplantation
#7
Marie-Cécile Fournier, Yohann Foucher, Paul Blanche, Christophe Legendre, Sophie Girerd, Marc Ladrière, Emmanuel Morelon, Fanny Buron, Lionel Rostaing, Nassim Kamar, Georges Mourad, Valérie Garrigue, Grégoire Couvrat-Desvergnes, Magali Giral, Etienne Dantan
BACKGROUND: Informing kidney transplant recipients of their prognosis and disease progression is of primary importance in a patient-centred vision of care. By participating in decisions from the outset, transplant recipients may be more adherent to complex medical regimens due to their enhanced understanding. METHODS: We proposed to include repeated measurements of serum creatinine (SCr), in addition to baseline characteristics, in order to obtain dynamic predictions of the graft failure risk that could be updated continuously during patient follow-up...
March 11, 2019: Nephrology, Dialysis, Transplantation
#8
Rukshana Shroff, Francis Calder, Sevcan Bakkaloğlu, Evi V Nagler, Sam Stuart, Lynsey Stronach, Claus P Schmitt, Karl H Heckert, Pierre Bourquelot, Ann-Marie Wagner, Fabio Paglialonga, Sandip Mitra, Constantinos J Stefanidis
BACKGROUND: There are three principle forms of vascular access available for the treatment of children with end stage kidney disease (ESKD) by haemodialysis: tunnelled catheters placed in a central vein (central venous lines, CVLs), arteriovenous fistulas (AVF), and arteriovenous grafts (AVG) using prosthetic or biological material. Compared with the adult literature, there are few studies in children to provide evidence based guidelines for optimal vascular access type or its management and outcomes in children with ESKD...
March 11, 2019: Nephrology, Dialysis, Transplantation
#9
Rajiv Agarwal
BACKGROUND: Chronic kidney disease (CKD) is characterized by accelerated aging, but the age-related changes in body composition and its modification by sex and race are unclear. METHODS: We assembled a cohort of 516 patients with CKD and 45 healthy controls and serially measured body composition using air-displacement plethysmography for up to 6 years. Mixed models were used to evaluate simultaneously the baseline and longitudinal changes in body composition as influenced by age, sex and race...
March 7, 2019: Nephrology, Dialysis, Transplantation
#10
Eleni Frangou, Agathi Varnavidou-Nicolaidou, Panayiotis Petousis, Andreas Soloukides, Elena Theophanous, Isavella Savva, Nicos Michael, Elpida Toumasi, Dora Georgiou, Galatia Stylianou, Richard Mean, Natasa Anastasiadou, Yiannis Athanasiou, Michalis Zavros, Kyriacos Kyriacou, Constantinos Deltas, Vassilis Hadjianastassiou
BACKGROUND: Complement factor H-related protein 5 (CFHR5) nephropathy is an inherited renal disease characterized by microscopic and synpharyngitic macroscopic haematuria, C3 glomerulonephritis and renal failure. It is caused by an internal duplication of exons 2-3 within the CFHR5 gene resulting in dysregulation of the alternative complement pathway. The clinical characteristics and outcomes of transplanted patients with this rare familial nephropathy remain unknown. METHODS: This is a retrospective case series study of 17 kidney transplant patients with the established founder mutation, followed-up over a span of 30 years...
March 7, 2019: Nephrology, Dialysis, Transplantation
#11
Francesco Locatelli, Lucia Del Vecchio
Prolyl-hydroxylase (PHD) inhibitors (PHD-I) are the most appealing drugs undergoing clinical development for the treatment of anaemia in patients with chronic kidney disease. PHD inhibition mimics the exposure of the body to hypoxia and activates the hypoxia-inducible factor system. Among many other pathways, this activation promotes the production of endogenous erythropoietin (EPO) and the absorption and mobilization of iron. PHD-I are given orally and, differing from erythropoiesis-stimulating agents (ESAs), they correct and maintain haemoglobin levels by stimulating endogenous EPO production...
March 7, 2019: Nephrology, Dialysis, Transplantation
#12
Adrian M Whelan, Elaine Ku
No abstract text is available yet for this article.
March 5, 2019: Nephrology, Dialysis, Transplantation
#13
Allyson Hart, Kirsten L Johansen
No abstract text is available yet for this article.
March 4, 2019: Nephrology, Dialysis, Transplantation
#14
Chava L Ramspek, Ype de Jong, Friedo W Dekker, Merel van Diepen
BACKGROUND: Prediction tools that identify chronic kidney disease (CKD) patients at a high risk of developing kidney failure have the potential for great clinical value, but limited uptake. The aim of the current study is to systematically review all available models predicting kidney failure in CKD patients, organize empirical evidence on their validity and ultimately provide guidance in the interpretation and uptake of these tools. METHODS: PubMed and EMBASE were searched for relevant articles...
March 4, 2019: Nephrology, Dialysis, Transplantation
#15
Bruno Watschinger, Klemens Budde, Marta Crespo, Uwe Heemann, Luuk Hilbrands, Umberto Maggiore, Christophe Mariat, Rainer Oberbauer, Gabriel C Oniscu, Licia Peruzzi, Søren S Sorensen, Ondrej Viklicky, Daniel Abramowicz
Current proposals for waiting times for a renal transplant after malignant disease may not be appropriate. New data on malignancies in end-stage renal disease and recent diagnostic and therapeutic options should lead us to reconsider our current practice.
March 4, 2019: Nephrology, Dialysis, Transplantation
#16
Kirsten L Johansen
No abstract text is available yet for this article.
March 1, 2019: Nephrology, Dialysis, Transplantation
#17
James Fotheringham, Ayesha Sajjad, Vianda S Stel, Keith McCullough, Angelo Karaboyas, Martin Wilkie, Brian Bieber, Bruce M Robinson, Ziad A Massy, Kitty J Jager
BACKGROUND: On the first haemodialysis (HD) day after the 2-day break in three times a week (3×W) in-centre HD, mortality and hospitalization are higher. If longer HD sessions prescribed 3×W is associated with a reduction in these events is unknown. METHODS: HD session length in 19 557 prevalent European in-centre 3×W HD patients participating in the Dialysis Outcomes and Practice Patterns Study (1998-2011) were categorized into <200, 200-225, 226-250 or >250 min...
February 28, 2019: Nephrology, Dialysis, Transplantation
#18
Mark Lambie, Lucy Teece, David W Johnson, Michaela Petrie, Robert Mactier, Ivonne Solis-Trapala, John Belcher, Hilary L Bekker, Martin Wilkie, Ken Tupling, Louise Phillips-Darby, Simon J Davies
BACKGROUND: Risk of encapsulating peritoneal sclerosis (EPS) is strongly associated with the duration of peritoneal dialysis (PD), such that patients who have been on PD for some time may consider elective transfer to haemodialysis to mitigate the risk of EPS. There is a need to determine this risk to better inform clinical decision making, but previous studies have not allowed for the competing risk of death. METHODS: This study included new adult PD patients in Australia and New Zealand (ANZ; 1990-2010) or Scotland (2000-08) followed until 2012...
February 28, 2019: Nephrology, Dialysis, Transplantation
#19
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque, Gérard M London, Ziad Massy, Petro Ruggenenti, Esteban Porrini, Andrzej Wiecek, Carmine Zoccali, Francesca Mallamaci, Mads Hornum
No abstract text is available yet for this article.
February 28, 2019: Nephrology, Dialysis, Transplantation
#20
Davide Viggiano, Anna Capasso, Giovambattista Capasso
No abstract text is available yet for this article.
February 27, 2019: Nephrology, Dialysis, Transplantation
Fetching more papers... 
